YanLing HeExecutive Director in Translational Medicine at NovartisSpeaker
Agenda Sessions
Fireside Chat: Preclinical Insights into RNA-Targeting Therapies for Lp(a)-Mediated Cardiovascular Risk
, 4:45pmView SessionKEYNOTE PANEL: Bridging the Gap: Addressing Regulatory Challenges in Oligonucleotide Development
, 9:40amView Session